NLRC5 and non-small cell lung carcinoma: In our study, we verified that NLRC5 mediates malignant cell behaviors and carboplatin resistance through activating the PI3K/AKT signaling pathway via CEACAM1 in NSCLC cells under hypoxic conditions.